Abstract
Targeted DNA integration into known locations in the genome has potential advantages over the random insertional events typically achieved using conventional means of genetic modification. We investigated the possibility of obtaining a suspension cell culture of Arabidopsis thaliana carrying a site-specific integration of a target gene encoding modified human interferon (dIFN) using endonuclease Cas9. For the targeted insertion, we selected the region of the histone H3.3 gene (HTR5) with a high constitutive level of expression. Our results indicated that Cas9-induced DNA integration occurred with the highest frequency with the construction with donor DNA surrounded by homology arms and Cas9 endonuclease recognition sites. Among the monoclones of the four cell lines with knock-in studied, there is high heterogeneity in the level of expression and accumulation of the target protein. The accumulation of dIFN protein in cell lines with targeted insertions into the target region of the HTR5 gene does not statistically differ from the level of accumulation of dIFN protein in the group of lines with random integration of the transgene. However, one among the monoclonal lines with knock-in has a dIFN accumulation level above 2% of TSP, which is very high.
Highlights
IntroductionPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations
Despite the attractiveness of using higher plant cell cultures for the commercial production of biopharmaceuticals, the yield of recombinant protein in this expression system is still low compared to animal cell cultures
The problem of low yield can be solved by transient expression or expression of the target gene in chloroplasts [1,8]
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Recombinant proteins are foreign proteins produced in various expression systems. They are mainly used as pharmaceuticals for diagnostics, for the vaccination of humans or animals, and as drugs or monoclonal antibodies [1]. The ever-growing demand for recombinant proteins stimulates the development of various expression systems for the production of these proteins that meet the existing stringent standards. Recombinant proteins are mainly produced in traditional prokaryotic and eukaryotic systems such as Escherichia coli, several yeast species, and mammalian cell cultures.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have